Rapid Response Production service for research, process development, and bioproduction launched

13-Apr-2016

GE Healthcare’s Life Sciences business announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype ...

more

13-Nov-2014

GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases. Liver disease has almost no visible symptoms, and its progress ...

more

28-Jun-2012

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The goal ...

more

14-May-2012

GE Healthcare announced that it has completed the acquisition of Xcellerex, Inc., a supplier of manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals such ...

more

21-Mar-2012

GE Healthcare and BAC BV announced that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, is a ...

more

Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market

09-Mar-2012

GE Healthcare, a unit of GE announced it has reached an agreement to acquire Xcellerex, Inc. a supplier of innovative manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services ...

more

Expanding advanced cancer diagnostic and molecular imaging capabilities

19-Sep-2011

GE Healthcare, the health business of General Electric, announced its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of ...

more

30-Aug-2011

Gyros AB announced that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong. The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency ...

more

18-Aug-2011

GE Healthcare announced it has reached an agreement to acquire PAA Laboratories, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry. The acquisition of PAA Laboratories will allow GE Healthcare to ...

more

Results from 5.5 year follow up of recurrence of bladder cancer

16-May-2011

Photocure announced the results from a 5.5 year follow up of recurrence in patients with Non Muscle Invasive Bladder Cancer( NMIBC) showing a long term benefit of the use of Hexvix compared to patients who received white light cystoscopy alone. After a follow-up up period up to 5.5 years, the ...

more